Risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutated patients: An evidence-based approach on what women should know

Claudia Marchetti, F. De Felice, S. M. Boccia, A. Romito, C. M. Sassu, M. G. Porpora, L. Muzii, V. Tombolini, P. Benedetti Panici

Risultato della ricerca: Contributo in rivistaArticolo in rivista

Abstract

This review is focused on the ovarian cancer risk reduction management in BRCA mutation carriers and is intended to assist with clinical decision-making. Obviously, treatment decisions must be based on the available evidence. Despite risk-reducing salpingo-oophorectomy is firmly recommended, several separate questions can be raised to address the variety of intense controversy of this approach. A special emphasis lies in the effective preventive surgical measure against ovarian cancer risk, in an attempt to detect the optimal timing and mitigate the impact on patients. The long term implications of risk-reducing salpingo-oophorectomy as well as hormone replacement therapy are also actively debated. This is expected to represent an opportunity for improved management modelling of BRCA mutated patients.
Lingua originaleEnglish
pagine (da-a)1-5
Numero di pagine5
RivistaCancer Treatment Reviews
Volume61
DOI
Stato di pubblicazionePubblicato - 2017

Keywords

  • BRCA
  • Chemoprevention
  • Hormone replacement therapy
  • Salpingo-oophorectomy
  • Mutation
  • Ovarian cancer
  • Risk-reducing surgery
  • Hysterectomy

Fingerprint

Entra nei temi di ricerca di 'Risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutated patients: An evidence-based approach on what women should know'. Insieme formano una fingerprint unica.

Cita questo